PIPRAM ® Pipemidic acid

PIPRAM ® is a drug based on pipemidic acid

THERAPEUTIC GROUP: Antibacterial for systemic use

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications PIPRAM ® Pipemidic acid

PIPRAM ® is indicated in the treatment of urinary tract infections, both high and low, sustained by microorganisms sensitive to pipemidic acid.

Mechanism of action PIPRAM ® Pipemidic acid

Pipemidic acid, the active ingredient of PIPRAM ® is an antimicrobial chemotherapeutic belonging structurally to the category of quinolones particularly used in the clinical field in the treatment of urinary tract infections.

These indications derive from the particular pharmacokinetic profile of pipemidic acid, which taken orally and absorbed from the gastrointestinal tract, through the circulatory torrent reaches unchanged the renal environment by being filtered at the glomerular level.

Persistence at the urinary level allows pipemidic acid to carry out its antibiotic action by inhibiting the activity of enzymes such as DNA gyrase and DNA topoisomerases, normally involved in the mechanisms of bacterial DNA replication, therefore in proliferative ones.

In this way the antibacterial activity is realized, supported also by the control of the diffusion of the resistance mechanisms implemented by pipemidic acid through the inhibition of the diffusion of the plasmidic DNA.

Studies carried out and clinical efficacy

ANTIBIOTIC THERAPY AND DRUG RESISTANCE

Pak J Pharm Sci. 2013 Jan; 26 (1): 11-5.

Interesting study that demonstrates how the inappropriate use of antibiotics can determine the appearance of microbial strains, isolated from urine, generally resistant to different antibiotics.

Therefore, it is suggested, also in the case of pipemidic acid therapy, to perform a culture test with antibiogram before administering the drug.

GENOTOSSIC POTENTIAL OF PIPEMIDIC ACID

Arch Med Res. 1998 Autumn; 29 (3): 235-40.

Important work that focuses on the study of the genotoxic potential of some antibiotics, including pipemidic acid induced by the various cells.

The study shows that in certain cases, it would be appropriate to consider the potential genotoxicity, generally determined by the pro-oxidant load of the drug, among the side effects of the therapy.

DETECTION OF PIPEMIDIC ACID AND DEFINITION OF DOSAGES

J Clin Lab Anal. 2010; 24 (5): 327-33.

Technical study that evaluates the use of new pipemidic acid detection systems in urine. These works are important to better clarify the pharmacokinetic characteristics of the active ingredient and the consequent definition of the dosages to be used.

Method of use and dosage

PIPRAM ®

400 mg hard capsules of pipemidic acid.

PIPRAM ® based therapy should be defined by your doctor based on the patient's clinical characteristics.

In principle, the intake of 400 mg of pipemidic acid twice a day and preferably after meals should guarantee a regression of symptoms in a few days of therapy.

In order to avoid the possible occurrence of recurrences, it would be advisable to prolong the therapy for a few days beyond the disappearance of the symptoms.

Warnings PIPRAM ® Pipemidic acid

Like any antibiotic therapy, even for those based on pipemidic acid, medical supervision and a careful checkup are necessary to assess the possible presence of conditions incompatible with the therapy itself.

The photosensitising power of the active ingredient could expose the skin of treated patients exposed to ultraviolet radiation to the risk of burns and dermatological reactions.

It should also be noted that the ability, albeit rare, of quinolones to determine tendinitis in particularly susceptible patients such as the elderly.

PREGNANCY AND BREASTFEEDING

Given the absence of clinical trials able to accurately reveal the safety profile of pipemidic acid on the fetus accidentally exposed to the drug, it is advisable to avoid the use of PIPRAM ® during pregnancy and in the subsequent period of breastfeeding.

In cases of need, strict supervision by your gynecologist is necessary.

Interactions

Although the use of PIPRAM ® is generally safe and free of clinically relevant interactions, in order to ensure maximum efficacy of the therapy it would be advisable to avoid the simultaneous intake of preparations, foods and active ingredients containing divalent metals, such as magnesium, aluminum, calcium, iron and zinc known the chelating qualities of the latter with respect to pipemidic acid.

Different studies, although still experimental, also show pharmacological interactions of pipemidic acid with erythromycin, glibenclamide, probenecid and H2 antagonists.

PIPRAM ® Contraindications Pipemidic acid

The use of PIPRAM ® is contraindicated in patients hypersensitive to the active substance or to any of its excipients and in children.

Undesirable effects - Side effects

The use of PIPRAM ®, especially when prolonged over time, could lead to the appearance of nausea, vomiting, diarrhea, abdominal pain, dyspepsia and only rarely more serious side effects such as pseudomembranous colitis or dermatological and hepatotoxic adverse reactions.